APOE Genotype (E2 / E3 / E4)

Beschrijving

Clinical purpose

The Apolipoprotein E (APOE) gene plays a key role in lipid transport, neuronal repair, and amyloid clearance in the brain. Certain APOE variants, particularly APOE ε4, are associated with an increased risk of late-onset Alzheimer’s disease, while ε2 may confer relative protection.

This test is intended for:

• Alzheimer’s disease risk assessment
• Neurodegeneration risk stratification
• Preventive and personalized health planning
• Clinical decision support in cognitive evaluation

What is analysed

• APOE genotypes: ε2 / ε3 / ε4
• Detection of common genotype combinations (e.g. ε3/ε4, ε4/ε4)

Sample & methodology

• Sample type: Serum or whole blood
• Methodology: PCR-based genotyping
• Turnaround time: Approximately 7–10 working days

Important clinical note

APOE genotyping provides risk information, not a diagnosis. Many individuals with APOE ε4 never develop Alzheimer’s disease, and Alzheimer’s disease can occur in individuals without ε4. Results should always be interpreted in combination with clinical findings and, where appropriate, biochemical biomarkers.

Consent requirement

Because this is a genetic test, informed consent is required prior to analysis, in accordance with applicable genetic testing regulations.

Suitable for postal submission.